RAPT RAPT Therapeutics, Inc.

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.

$34.67  -0.80 (-2.26%)
As of 06/22/2021 15:59:56 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/28/2019
Outstanding shares:  25,009,007
Average volume:  2,388,111
Market cap:   $864,561,372
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    75382E109
ISIN:        US75382E1091
Sedol:      BK5T6R0
Valuation   (See tab for details)
PE ratio:   -15.77
PB ratio:   9.62
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy